- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00177957
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
June 8, 2017 updated by: Yohei Doi, University of Pittsburgh
The aims of this study are to:
- Determine the risk factors for multidrug resistance in bloodstream isolates of Gram negative bacilli
- Determine the mechanisms of multidrug resistance in bloodstream isolates of Gram negative bacilli
- Determine the risk factors for failure of prompt clearance of the blood of Gram negative bacteria
- Determine the survival of patients with Gram negative bacteremia
- Determine if failure of prompt clearance of the blood of Gram negative bacteria is a predictor of mortality following this infection
Study Overview
Status
Completed
Conditions
Detailed Description
The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage within 14 days of onset of bacteremia, microbiological data and resistance patterns, choice of antibiotics once organism identified, suspected source of bacteremia, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history (please see attached clinical data collection worksheet dated 4/2005).
We will also collect information retrospectively for one year and prospectively for one year.
The bacteria in the patient's blood cultures will be subcultured (after the diagnosis has been obtained since the microbiology lab would otherwise destroy the culture) and provided to the honest broker who will deidentify the specimen and link it to the medical information collected (which will also be deidentified by the honest broker).
The following evaluation will be performed on these samples.
The minimal inhibitory concentration of the antibiotic used in treatment will be performed by the E-Test method (AB Biodisk, Solna, Sweden).
Specific mechanisms of antimicrobial resistance will be studied with emphasis on the presence of beta-lactamases produced by the bacteria.
This evaluation will be performed by analytical isoelectric focusing techniques as well as PCR and gene sequencing analysis to determine genes encoding beta-lactamases.
Biologic samples will be under the control of the principal investigator of this research project.
All samples provided to the investigators are deidentified by the honest broker and will be coded with numbers.
The information linking these code numbers to the corresponding subjects' identities will be kept in a separate, secure location that only the honest broker has access to.
The investigators on this study will keep the samples indefinitely.
Samples will be kept in the investigator's laboratory located in Scaife Hall, room 812, 3500 Terrace Street.
At no time with the research investigators have access to any patient identifiers.
Study Type
Observational
Enrollment (Anticipated)
600
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
patients with gram negative bacteremia
Description
Inclusion Criteria:
- All patients at the aforementioned institutions that have Gram negative bacteremia will be included in the study.
- Women with childbearing potential will also be included in this study. Since this is an observational study, no added risk is conferred to the woman or potential progeny. HIV serostatus will not be specifically investigated for participation in this study.
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
outcome of dead or alive post treatment
Time Frame: December 2020
|
dead or alive
|
December 2020
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Yohei Doi, MD, University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Primary Completion (Actual)
May 1, 2016
Study Completion (Actual)
May 1, 2016
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 15, 2005
Study Record Updates
Last Update Posted (Actual)
June 9, 2017
Last Update Submitted That Met QC Criteria
June 8, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB # 0504090
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
not sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gram-Negative Bacterial Infections
-
Seoul National University HospitalCompletedMultidrug-resistant Gram-negative Bacteria InfectionKorea, Republic of
-
University of PittsburghMerck Sharp & Dohme LLCWithdrawnSurveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream IsolatesGram-negative Bacterial InfectionsUnited States
-
Hoffmann-La RocheCompletedGram-negative Bacterial InfectionsUnited States
-
University of PittsburghCelgene CorporationCompletedGram-negative Bacterial InfectionsUnited States
-
Hospital Barros Luco TrudeauFondo Nacional de Desarrollo Científico y Tecnológico, ChileUnknownGram Negative Bacterial InfectionsChile
-
PfizerAllerganTerminatedGram-negative Bacterial InfectionUnited States, Hungary, Slovakia, Taiwan, India, Estonia, Greece, Italy
-
PfizerCompletedGram-negative Bacterial InfectionAustralia
-
Singapore General HospitalNational Medical Research Council (NMRC), SingaporeRecruitingAntibiotic TherapySingapore
-
PfizerRecruitingGram-negative Bacterial InfectionsSpain, Taiwan, United States, Hungary, India, China, Turkey, Greece, Czechia
-
Parc de Salut MarCompletedMultidrug Resistant Gram Negative Bacterial InfectionsSpain